Patents by Inventor Marvin R. Leanna

Marvin R. Leanna has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SYNTHETIC ROUTE TO ANTI-VIRAL AGENTS
    Publication number: 20200095230
    Abstract: The invention provides methods of synthesizing a viral protease inhibitor in high yield, without using expensive catalysts or challenging reaction conditions.
    Type: Application
    Filed: September 27, 2019
    Publication date: March 26, 2020
    Inventors: Russell D. Cink, Kirill A. Lukin, Marvin R. Leanna, Matthew J. Pelc, Timothy B. Towne, Dennie S. Welch, Kenneth M. Engstrom, Matthew M. Ravn, Richard D. Bishop, Gang Zhao, Jianzhang Mei, Jeff M. Kallemeyn, David R. Hill, Michael J. Abrahamson, Westin H. Morrill
  • Synthetic route to anti-viral agents
    Patent number: 10442792
    Abstract: The invention provides methods of synthesizing a viral protease inhibitor in high yield, without using expensive catalysts or challenging reaction conditions.
    Type: Grant
    Filed: September 17, 2018
    Date of Patent: October 15, 2019
    Assignee: AbbVie Inc.
    Inventors: Russell D. Cink, Kirill A. Lukin, Marvin R. Leanna, Matthew J. Pelc, Timothy B. Towne, Dennie S. Welch, Kenneth M. Engstrom, Matthew M. Ravn, Richard D. Bishop, Gang Zhao, Jianzhang Mei, Jeff M. Kallemeyn, David R. Hill, Michael J. Abrahamson, Westin H. Morrill
  • SYNTHETIC ROUTE TO ANTI-VIRAL AGENTS
    Publication number: 20190084966
    Abstract: The invention provides methods of synthesizing a viral protease inhibitor in high yield, without using expensive catalysts or challenging reaction conditions.
    Type: Application
    Filed: September 17, 2018
    Publication date: March 21, 2019
    Inventors: Russell D. Cink, Kirill A. Lukin, Marvin R. Leanna, Matthew J. Pelc, Timothy B. Towne, Dennie S. Welch, Kenneth M. Engstrom, Matthew M. Ravn, Richard D. Bishop, Gang Zhao, Jianzhang Mei, Jeff M. Kallemeyn, David R. Hill, Michael J. Abrahamson, Westin H. Morrill
  • Synthetic route to anti-viral agents
    Patent number: 10077256
    Abstract: The invention provides methods of synthesizing a viral protease inhibitor in high yield, without using expensive catalysts or challenging reaction conditions.
    Type: Grant
    Filed: November 6, 2017
    Date of Patent: September 18, 2018
    Assignee: AbbVie Inc.
    Inventors: Russell D. Cink, Kirill A. Lukin, Marvin R. Leanna, Matthew J. Pelc, Timothy B. Towne, Dennie S. Welch, Kenneth M. Engstrom, Matthew M. Ravn, Richard D. Bishop, Gang Zhao, Jianzhang Mei, Jeff M. Kallemeyn, David R. Hill, Michael J. Abrahamson, Westin H. Morrill
  • SYNTHETIC ROUTE TO ANTI-VIRAL AGENTS
    Publication number: 20180057482
    Abstract: The invention provides methods of synthesizing a viral protease inhibitor in high yield, without using expensive catalysts or challenging reaction conditions.
    Type: Application
    Filed: November 6, 2017
    Publication date: March 1, 2018
    Inventors: Russell D. Cink, Kirill A. Lukin, Marvin R. Leanna, Matthew J. Pelc, Timothy B. Towne, Dennie S. Welch, Kenneth M. Engstrom, Matthew M. Ravn, Richard D. Bishop, Gang Zhao, Jianzhang Mei, Jeff M. Kallemeyn, David R. Hill, Michael J. Abrahamson, Westin H. Morrill
  • Synthetic route to anti-viral agents
    Patent number: 9809576
    Abstract: The invention provides methods of synthesizing a viral protease inhibitor in high yield, without using expensive catalysts or challenging reaction conditions.
    Type: Grant
    Filed: July 17, 2015
    Date of Patent: November 7, 2017
    Assignee: AbbVie Inc.
    Inventors: Russell D. Cink, Kirill A. Lukin, Marvin R. Leanna, Matthew J. Pelc, Timothy B. Towne, Dennie S. Welch, Kenneth M. Engstrom, Matthew M. Ravn, Richard D. Bishop, Gang Zhao, Jianzhang Mei, Jeff M. Kallemeyn, David R. Hill, Michael J. Abrahamson, Westin H. Morrill
  • Process for the preparation of indazolyl ureas that inhibit Vanilloid subtype 1 (VR1) receptors
    Patent number: 8519186
    Abstract: The present invention relates to a process of preparing indazolyl ureas that are useful as antagonists of the vanilloid receptor subtype 1 (VR1).
    Type: Grant
    Filed: October 28, 2010
    Date of Patent: August 27, 2013
    Assignee: AbbVie Inc.
    Inventors: Kirill A. Lukin, Margaret Chi-Ping Hsu, Dilinie P. Fernando, Brian J. Kotecki, Marvin R. Leanna
  • Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
    Patent number: 8071762
    Abstract: The present invention discloses novel compounds of general formula (I) or a pharmaceutically acceptable salt or prodrug thereof (in which X1-X5, R5-R8b, Z1-Z2 and Ar1 are defined herein), a method for inhibiting the VR1 receptor in mammals using these compounds, a method for controlling pain in mammals, and pharmaceutical compositions including those compounds and a process for making those compounds.
    Type: Grant
    Filed: April 30, 2008
    Date of Patent: December 6, 2011
    Assignee: Abbott Laboratories
    Inventors: Arthur R. Gomtsyan, Erol K. Bayburt, Chih-Hung Lee, John R. Koenig, Robert G. Schmidt, Kirill A. Lukin, Gilles Chambournier, Margaret Chi-Ping Hsu, Marvin R. Leanna, Russell D. Cink
  • PROCESS FOR THE PREPARATION OF INDAZOLYL UREAS THAT INHIBIT VANILLOID SUBTYPE 1 (VR1) RECEPTORS
    Publication number: 20110040102
    Abstract: The present invention relates to a process of preparing indazolyl ureas that are useful as antagonists of the vanilloid receptor subtype 1 (VR1).
    Type: Application
    Filed: October 28, 2010
    Publication date: February 17, 2011
    Applicant: ABBOTT LABORATORIES
    Inventors: Kirill A. Lukin, Margaret Chi-Ping Hsu, Dilinie P. Fernando, Brian J. Kotecki, Marvin R. Leanna
  • Process for the preparation of indazolyl ureas that inhibit Vanilloid subtype1 (VR1) receptors
    Patent number: 7847104
    Abstract: The present invention relates to a process of preparing indazolyl ureas that are useful as antagonists of the vanilloid receptor subtype 1 (VR1).
    Type: Grant
    Filed: April 13, 2007
    Date of Patent: December 7, 2010
    Assignee: Abbott Laboratories
    Inventors: Kirill A. Lukin, Margaret Chi-Ping Hsu, Dilinie P. Fernando, Brian J. Kotecki, Marvin R. Leanna
  • Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
    Patent number: 7375126
    Abstract: The present invention discloses novel compounds of general formula (I) or a pharmaceutically acceptable salt or prodrug thereof (in which X1-X5, R5-R8b, Z1-Z2 and Ar1 are defined herein), a method for inhibiting the VR1 receptor in mammals using these compounds, a method for controlling pain in mammals, and pharmaceutical compositions including those compounds and a process for making those compounds.
    Type: Grant
    Filed: June 9, 2004
    Date of Patent: May 20, 2008
    Assignee: Abbott Laboratories
    Inventors: Arthur R. Gomtsyan, Erol K. Bayburt, Chih-Hung Lee, John R. Koenig, Robert G. Schmidt, Kirill A. Lukin, Margaret Chi-Ping Hsu, Marvin R. Leanna, Russell D. Cink, Gilles Chambournier